Skip to content
  • Clinical Studies
  • Schedule M
  • Stability Studies
  • Pharma GMP
  • Pharma Tips
  • Pharma Books
  • Pharma Validation
  • Pharma Regulatory

SOP Guide for Pharma

The Ultimate Resource for Pharmaceutical SOPs and Best Practices

  • Home
  • SOP Guidelines
    • SOP Development
    • SOP Training
    • SOP Compliance Monitoring
    • SOP Revision Processes
    • Pharmaceutical SOP templates
    • GMP documentation SOP
    • Data integrity SOP pharma
    • Manufacturing SOP pharmaceutical
    • FDA SOP guidance
    • eQMS SOP workflows
  • Job Safety Analysis (JSA)
    • Oral Dosage Forms (Tablets & Capsules)
    • Oral Liquid Dosage Forms (Syrups, Elixirs, Suspensions, Emulsions)
    • Powder and Granule Dosage Forms
    • Topical Dosage Forms (Creams, Ointments, Gels, Lotions, Pastes)
    • Transdermal Dosage Forms (Patches)
  • Standard Test Procedures (STP)
  • GMP Audit Findings
    • Non-Compliance
      • SOP Absence
      • Revision Control
      • Non-Adherence
      • Poor Writing
      • Training Failure
      • Data Integrity Gaps
      • Mismatch Between SOPs and Practice
      • Critical Operations
      • Regulatory Change
      • Emergency Changes
      • Third-Party SOPs
      • Inspection Readiness
      • Deviation Handling
      • CAPA Integration
      • Validation Alignment
      • System Integration
      • Uncontrolled Distribution
      • SOP Implementation Gaps
      • SOP Alignment with Validation
      • Change Control Linkage
  • Toggle search form

API Manufacturing: SOP for Handling of Unplanned Events in GMP Areas – V 2.0

Posted on By

API Manufacturing: SOP for Handling of Unplanned Events in GMP Areas – V 2.0

Standard Operating Procedure for Handling of Unplanned Events in GMP Areas

Department API Manufacturing
SOP No. SOP/API/199/2025
Supersedes SOP/API/199/2022
Page No. Page 1 of 15
Issue Date 14/04/2025
Effective Date 16/04/2025
Review Date 14/04/2026

1. Purpose

To provide a systematic approach for identifying, documenting, evaluating, and managing unplanned events that occur in Good Manufacturing Practice (GMP) areas of API manufacturing, in order to mitigate risks to product quality and ensure timely resolution and regulatory compliance.

2. Scope

This SOP applies to all unplanned events observed in GMP manufacturing, packing, quality control, and

storage areas during operations. These may include environmental excursions, power interruptions, equipment breakdowns, procedural deviations, and utility failures.

3. Responsibilities

  • Initiator (Operator/Supervisor): Immediately identifies and documents the unplanned event.
  • Department Head: Evaluates preliminary impact and notifies QA.
  • QA Officer: Performs assessment, categorization, and initiates documentation and investigation.
  • QA Manager: Approves final disposition, ensures corrective/preventive actions are implemented.

See also  API Manufacturing: SOP for In-Process Sampling Technique - V 2.0

4. Accountability

The Head of Quality Assurance is accountable for ensuring that all unplanned events are properly managed, investigated, and closed as per defined timelines and in accordance with GMP guidelines.

5. Procedure

5.1 Identification and Initial Action

  1. Any GMP personnel observing an unplanned event must immediately:
    • Stop the process (if necessary)
    • Secure product and environment
    • Inform the area supervisor
  2. The supervisor shall record initial details in the Unplanned Event Notification Form (Annexure-1) and notify QA.

5.2 Classification of Unplanned Event

  1. QA shall classify the unplanned event based on impact:
    • Minor: No impact on product quality or GMP compliance
    • Major: Potential or confirmed impact on quality/process
    • Critical: Definite impact on product, requires immediate action or regulatory notification
  2. Classification shall be recorded in the Unplanned Event Register (Annexure-2).

5.3 Documentation and Evaluation

  1. The QA Officer shall:
    • Log the event in the tracking system
    • Assign a unique reference number (e.g., UE-API-2025-007)
    • Initiate the Unplanned Event Investigation Form (Annexure-3)
  2. Department Head and QA shall jointly perform impact assessment and risk evaluation using the Risk Assessment Template (Annexure-4).

5.4 Root Cause Analysis

  1. Use tools such as:
    • 5 Whys
    • Ishikawa (Fishbone) Diagram
  2. Document RCA in Section C of the Investigation Form and attach supporting evidence.
See also  API Manufacturing: SOP for Calibration and Maintenance of pH Meter - V 2.0

5.5 Corrective and Preventive Actions (CAPA)

  1. Define:
    • Corrective Actions: To address the current issue
    • Preventive Actions: To prevent recurrence
  2. QA shall approve CAPA plan and assign target dates and responsible persons.
  3. Track progress in the Unplanned Event CAPA Log (Annexure-5).

5.6 QA Review and Closure

  1. QA Manager shall:
    • Verify CAPA implementation
    • Ensure effectiveness checks
    • Review supporting documentation
  2. Closure shall be documented in the final section of the Investigation Form and approved by QA.

5.7 Trending and Reporting

  1. QA shall trend unplanned events monthly using the Event Trending Sheet (Annexure-6).
  2. Trends must be reviewed during:
    • Quarterly Quality Review Meetings
    • Annual Product Quality Review (PQR)

6. Abbreviations

  • GMP: Good Manufacturing Practices
  • QA: Quality Assurance
  • CAPA: Corrective and Preventive Action
  • RCA: Root Cause Analysis
  • PQR: Product Quality Review

7. Documents

  1. Unplanned Event Notification Form – Annexure-1
  2. Unplanned Event Register – Annexure-2
  3. Unplanned Event Investigation Form – Annexure-3
  4. Risk Assessment Template – Annexure-4
  5. Unplanned Event CAPA Log – Annexure-5
  6. Event Trending Sheet – Annexure-6

8. References

  • ICH Q10 – Pharmaceutical Quality System
  • EU GMP Chapter 1 – Quality System
  • 21 CFR 211.100 – Written Procedures
  • WHO Technical Report Series No. 981 – GMP for APIs
See also  API Manufacturing: SOP for QA Oversight During Manufacturing and Packaging - V 2.0

9. SOP Version

Version: 2.0

10. Approval Section

Prepared By Checked By Approved By
Signature
Date
Name
Designation
Department

11. Annexures

Annexure-1: Unplanned Event Notification Form

Date Time Area Description Initiator
12/04/2025 10:15 AM Granulation Room Power interruption during drying Rajesh Kumar

Annexure-2: Unplanned Event Register

Event ID Date Classification Status Closed On
UE-API-2025-007 12/04/2025 Major Closed 14/04/2025

Annexure-3: Unplanned Event Investigation Form

Event ID Description Initial Assessment RCA Summary QA Review
UE-API-2025-007 Equipment stopped during granulation Batch on hold Loose wire in panel Impact nullified

Annexure-4: Risk Assessment Template

Parameter Severity Probability Detectability Risk Score
Batch impact Medium Low High 6

Annexure-5: Unplanned Event CAPA Log

CAPA ID Action Owner Due Date Status
CAPA/2025/018 Replace panel wire Engineering 13/04/2025 Completed

Annexure-6: Event Trending Sheet

Month Minor Major Critical Total
March 2025 4 2 0 6

Revision History:

Revision Date Revision No. Details Reason Approved By
01/01/2022 1.0 Initial Release New SOP QA Head
14/04/2025 2.0 Added annexures and classification tiers Internal Audit Recommendation QA Head
API Manufacturing V 2.0 Tags:API batch record, API BMR, API calibration, API centrifuge, API cleaning, API crystallization, API deviation, API documentation, API drying, API equipment cleaning, API filtration, API GMP compliance, API granulation, API hold time, API impurities, API line clearance, API manufacturing, API process, API quality control, API reactor, API sampling, API solvent handling, API validation, API waste disposal, API yield

Post navigation

Previous Post: Sterile Injectable Manufacturing: SOP for Stability Testing of Finished Injectable Products – V 2.0
Next Post: Gel Manufacturing: SOP for Labeling Gel Tubes and Jars – V 2.0

Standard Operating Procedures V 1.0

  • Aerosols
  • Analytical Method Development
  • Bioequivalence Bioavailability Study
  • Capsule Formulation
  • Clinical Studies
  • Creams
  • Data Integrity
  • Dental Dosage Forms
  • Drug Discovery
  • Environment, Health and Safety
  • Formulation Development
  • Gels
  • Good Distribution Practice
  • Good Warehousing Practices
  • In-Process Control
  • Injectables
  • Liquid Orals
  • Liposome and Emulsion Formulations
  • Lotions
  • Lyophilized Products
  • Maintenance Dept.
  • Medical Devices
  • Metered-Dose Inhaler
  • Microbiology Testing
  • Nanoparticle Formulation
  • Nasal Spray Formulations
  • Nebulizers
  • Ocular (Eye) Dosage Forms
  • Ointments
  • Otic (Ear) Dosage Forms
  • Pharmacovigilance
  • Powder & Granules
  • Purchase Departments
  • Quality Assurance
  • Quality Control
  • Raw Material Stores
  • Regulatory Affairs
  • Tablet Manufacturing
  • Rectal Dosage Forms
  • Transdermal Patches
  • Vaginal Dosage Forms
  • Validations and Qualifications

Read SOPs in your Language:

 - 
Bengali
 - 
bn
English
 - 
en
Gujarati
 - 
gu
Hindi
 - 
hi
Malayalam
 - 
ml
Marathi
 - 
mr
Punjabi
 - 
pa
Tamil
 - 
ta
Telugu
 - 
te

NEW! Revised SOPs – V 2.0

  • Aerosols V 2.0
  • Analytical Method Development V 2.0
  • API Manufacturing V 2.0
  • BA-BE Studies V 2.0
  • Biosimilars V 2.0
  • Capsules V 2.0
  • Creams V 2.0
  • Elixers V 2.0
  • Gels V 2.0
  • Injectables V 2.0
  • Ointments V 2.0
  • Raw Material Warehouse V 2.0
  • Tablet Manufacturing V2.0

New Publication: A must for All.

Copyright © 2025 SOP Guide for Pharma.

Powered by PressBook WordPress theme

Go to mobile version